Grail, the company behind the Galleri multi-cancer early detection blood test, has watched its stock climb about 180% over the past six months, and the fuel behind the move is a favorable advisory vote at the FDA. You can read the full rundown over at MSN.

A quick word on what this company actually does, because it matters. Grail's test is built to spot dozens of cancers from a single blood draw, ideally before symptoms show up. The promise is enormous. Cancer caught early is, generally speaking, cancer that's cheaper to treat and more likely to survive. If Galleri works at scale, it changes medicine.

The catch, and there's always a catch, is the distance between a promising test and a profitable company. An advisory committee vote is one step, not the finish line. Full approval, Medicare coverage, insurance reimbursement, actual sales traction; each of those is its own hurdle, and each one has killed plenty of story stocks over the years. I watched biotech cousins of this trade come and go in the late '90s. The biology was real in some of them. The shareholders still lost money.

That's the distinction I'd urge you to hold onto. A stock up 180% in six months has already priced in a great deal of good news, and the MSN piece argues there's more room to run. Maybe there is. But "room to run" articles get written about stocks that have already run, and the entry price you pay today bears no relationship to the entry price the early buyers got. Their 180% gain tells you nothing about your next twelve months.

None of this means Grail is a bad company or that the test is a fraud. It means the stock is a bet on a sequence of future events going right, and sequences are fragile. If you believe in the science and want to own it, size the position like what it is: a speculation. Two or three percent of a portfolio, money you could watch go to zero without changing your retirement date. The other ninety-some percent stays in the boring, diversified core that doesn't need any FDA committee to keep compounding.

I've been doing this for forty years, and the pattern never changes. Genuine breakthroughs exist. Most people who chased them late still didn't make money, because they paid breakthrough prices for maybes.

As always, this is my perspective, not professional financial advice. Do your own homework before you buy anything.